John Newman
Stock Analyst at Canaccord Genuity
(2.12)
# 2,894
Out of 4,960 analysts
79
Total ratings
44.93%
Success rate
-6.69%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $589.48 | +44.19% | 17 | Jul 23, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.19 | +1,076.47% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $110.88 | +54.62% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $12.34 | +37.76% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.29 | +520.16% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.95 | +320.17% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $19.44 | +928.81% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $11.12 | +88.85% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $71.28 | +61.34% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.73 | +1,000.26% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $67.49 | -0.73% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $11.23 | +282.90% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.01 | +395.05% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $38.80 | +13.40% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $16.11 | +135.95% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.81 | +364.72% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $12.27 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Jul 23, 2025
Maintains: Buy
Price Target: $850
Current: $589.48
Upside: +44.19%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.19
Upside: +1,076.47%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $110.88
Upside: +54.62%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $12.34
Upside: +37.76%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.29
Upside: +520.16%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.95
Upside: +320.17%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $19.44
Upside: +928.81%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $11.12
Upside: +88.85%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $71.28
Upside: +61.34%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.73
Upside: +1,000.26%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $67.49
Upside: -0.73%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $11.23
Upside: +282.90%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.01
Upside: +395.05%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $38.80
Upside: +13.40%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $16.11
Upside: +135.95%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.81
Upside: +364.72%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $12.27
Upside: -